Targeted Vectors for Gene Therapy of Cancer and Retroviral Infections

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 6, Issue 3, 1996, Pages 267-286

  Walther, Wolfgang ^a   Stein, Ulrike ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Cancer therapy; Cell type specific; Gene targeting; Gene therapy; Retroviral disease

Indexed keywords

ANIMAL; GENE THERAPY; GENE VECTOR; HUMAN; NEOPLASM; RETROVIRUS INFECTION; REVIEW;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; RETROVIRIDAE INFECTIONS;

EID: 0030342315     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02761707     Document Type: Review

References (65)

1. Anderson, W. F. (1992) Human gene therapy. Science 256, 808-813.
2. Mulligan, R. C. (1993) The basic science of gene therapy. Science 260, 926-932.
3. Hart, I. R. (1995) Direct transfer of DNA as an approach to gene therapy of cancer. Gene Ther. 2, 592.
4. Crystal, R. G. (1995) Transfer of genes to humans: early lessons and obstacles to success. Science 270, 404-410.
5. Bushman, F. (1995) Targeting retroviral integration. Science 267, 1443-1444.
6. Friedmann, T. and Yee, J.-K. (1995) Pseudotyped retroviral vectors for studies of human gene therapy. Nature Med. 1, 275-277.
7. Kasahara, N., Dozy, A. M., and Kan, Y. W. (1994) Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376.
8. Salmons, B. and Günzburg, W. H. (1993) Targeting of retroviral vectors for gene therapy. Hum. Gene Ther. 4, 129-141.
9. Günzburg, W. H. and Salmons, B. (1992) Factors controlling the expression of mouse mammary tumour virus. Biochem. J. 283, 625-632.
10. Sparmann, G., Walther, W., Günzburg, W. H., Uckert, W., and Salmons, B. (1994) Conditional expression of human TNF-a: a system for inducible cytotoxicity. Int. J. Cancer 59, 103-107.
11. Dale, T. C., Krnacik, M. J., Schmidhauser, C., Yang, C. L.-Q., Bissel, M. J., and Rosen, J. M. (1992) High-level expression of the rat whey acidic protein gene is mediated by elements in the promoter and 3′ untranslated region. Mol. Cell. Biol. 12, 905-914.
12. Günzburg, W. H., Salmons, B., Zimmermann, B., Muller, M., Erfle, V., and Brem, G. (1991) A mammary-specific promoter directs expression of growth hormone not only to the mammary gland but also Bergman glia cells in transgenic mice. Mol. Endocrinol. 5, 123-133.
13. Kolb, A. F., Günzburg, W. H., Albang, R., Brem, G., Erfle, V., and Salmons, B. (1994) A negative regulatory element in the mammary specific whey acidic protein promoter. J. Cell. Biochem. 55, 245-261.
14. Salmons, B., Saller, R. M., Baumann, J. G., and Günzburg, W. H. (1995) Construction of retroviral vectors for targeted delivery and expression of therapeutic genes. Leukemia 9, Suppl. 1, S53-S60.
15. Schmitt-Ney, M., Doppler, W., Ball, R. K., and Groner, B. (1991) β-casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor. Mol. Cell. Biol. 11, 3745-3755.
16. Abe, M. and Kufe, D. (1993) Characterization of cis-acting elements regulating the transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc. Natl. Acad. Sci. USA 90, 282-286.
17. Manome, Y., Ohno, T., Miyako, A., Hagen, M. F., Fine, H. A., and Kufe, D. W. (1995) Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Gene Ther. 2, 685, A 051.
18. Chen, L., Chen, D., Manome, Y., Dong, Y., Fine, H. A., and Kufe, D. W. (1995) Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J. Clin. Invest. 96, 2775-2782.
19. Strauss, M. (1994) Liver-directed gene therapy: prospects and problems. Gene Ther. 1, 156-164.
20. Huber, B. E., Richards, C. A., and Krenitsky, T. A. (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA 88, 8039-8043.
21. Ido, A., Nakata, K., Kato, Y., Nakao, K., Murata, K., Fujita, M., Ishii, N., Tamaoki, T., Shiku, H., and Nagataki, S. (1995) Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res. 55, 3105-3109.
22. Kaneko, S., Hallenbeck, P., Kotani, T., Nakabayashi, H., Mc Garrity, G., Tamaoki, T., Anderson, F. W., and Chiang, Y. L. (1995) Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55, 5283-5287.
23. Thompson, J. A., Grunert, F., and Zimmermann, W. (1991) Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal. 5, 344-366.
24. Schrewe, H., Thompson, J., Bona, M., Hefta, L. J., Maruya, A., Hassauer, M., Shively, J. E., von Kleist, S., and Zimmermann, W. (1990) Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol. Cell. Biol. 10, 2738-2748.
25. Osaki, T., Tanio, Y., Tachibana, I., Hosoe, S., Kumagai, T., Kawase, I., Oikawa, S., and Kishimoto, T. (1994) Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54, 5258-5261.
26. Richards, C. A., Austin, E. A., and Huber, B. E. (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6, 881-895.
27. Garver, R. I., Goldsmith, K. T., Rodu, B., Hu P.-C., Sorscher, E. J., and Curiel, D. T. (1994) Strategy for achieving selective killing of carcinomas. Gene Ther. 1, 46-50.
28. Korner, A. and Pawalek, J. (1982) Mammalian tyrosinase catalyzes three reactions in the biosynthesis of melanin. Science 217, 1163-1165.
29. Vile, R. G. and Hart, I. R. (1993) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53, 962-967.
30. Vile, R., Miller, N., Chernjovsky, Y., and Hart, I. R. (1994) A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1, 307-316.
31. Vile, R. G., Nelson, J. A., Castleden, S., Chong, H., and Hart, I. R. (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSV-tk gene involves an immune component. Cancer Res. 54, 6228-6234.
32. Sauerwald, A., Hoesche, C., Oschwald, R., and Kilimann, M. W. (1990) The 5′-flanking region of the synapsin I gene. A G+C-rich, TATA-and CAAT-less, phylogenetically conserved sequence with cell type-specific promoter function. J. Biol. Chem. 265, 14,932-14,937.
33. Chang, C. D., Takeda, T., Mukai, H., Shuntoh, H., Kuno, T., and Tanaka, C. (1992) Molecular cloning and characterization of the promoter region of the calcineurin A alpha gene. Biochem. J. 288, 801-805.
34. Batchelor, A. H. and O'Hare, P. (1990) Regulation and cell-type-specific activity of a promoter located upstream of the latency-associated transcript of herpes simplex virus type 1. J. Virol. 64, 3269-3279.
35. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayer, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474-5478.
36. Riegman, P. H. J., Vliestra, R. J., van der Korput, J. A. G. M., Brinkmann, A. O., and Trapman, J. (1991) The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 5, 1921-1930.
37. Maxwell, I. H., Glode, L. M., and Maxwell, F. (1991) Expression of the diphtheria toxin A-chain coding sequence under the control of promoters and enhancers from immunoglobulin genes as a means of directing toxicity to B-lymphoid cells. Cancer Res. 51, 4299-4304.
38. Engelhardt, J. F., Kellum, M. J., Bisat, F., and Pitha, P. M. (1990) Retrovirus vector-targeted inducible expression of human β-interferon gene to B-cells. Virology 178, 419-428.
39. Hollywood, D. P. and Hurst, H. C. (1993) A novel transcription factor, OB2-1, is required for overexpression of the oncogene c-erb-2 in mammary tumor lines. EMBO J. 12, 2369-2375.
40. Harris, J. D., Gutierrez, A. A., Hurst, H. C., Sikora, K., and Lemoine, N. R. (1994) Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther. 1, 170-175.
41. Kumagai, T., Tanio, Y., Osaki, T., Horai, T., and Kishimoto, T. (1995) Gene therapy for small cell lung cancer cells overexpressing myc family oncogenes by tumor-specific expression of the herpes simplex virus thymidine kinase gene. Gene Ther. 2, 681.
42. Franklin, G. C., Donovan, M., Adam, G. I., Holmgren, L., Pfeifer-Ohlsson, S., and Ohlsson, R. (1991) Expression of the human PDGF-B gene is regulated by both positively and negatively acting cell type-specific regulatory elements located in the first intron. EMBO J. 10, 1365-1373.
43. Kohno, K., Sato, S.-I., Takano, H., Matsuo, K.-I., and Kuwano, M. (1989) The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophys. Res. Commun. 165, 1415-1421.
44. Stein, U., Walther, W., and Wunderlich, V. (1994) Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. Eur. J. Cancer 30, 1541-1545.
45. Stein, U., Walther, W., and Shoemaker, R. H. (1996) Vincristine induction of mutant and wild-type human multidrug-resistance promoters is cell-type specific and dose-dependent. J. Cancer Res. Clin. Oncol. 122, 275-282.
46. Boothman, D. A., Lee, I. W., and Sahijdak, W. M. (1994) Isolation of an X-ray-responsive element in the promoter region of tissue-type plasminogen activator: potential uses of X-ray-responsive elements for gene therapy. Radiat. Res. 138(1 Suppl.), S 68-71.
47. Hallahan, D. E., Mauceri, H. J., Seung, L. P., Dunphy, E. J., Wayne, J. D., Hanna, N. N., Toledano, A., Hellman, S., Kufe, D. W., and Weichselbaum, R. R. (1995) Spatial and temporal control of gene therapy using ionizing radiation. Nature Med. 1, 786-791.
48. Seung, L. P., Mauceri, H. J., Beckett, M. A., Hallahan, D. E., Hellman, S., and Weichselbaum, R. R. (1995) Genetic radiotherapy overcomes tumor resistance to cytotoxic agents. Cancer Res. 55, 5561-5565.
49. Joki, T., Nakamura, M., and Ohno, T. (1995) Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. Hum. Gene Ther. 6, 1507-1513.
50. Takahashi, T., Namiki, Y., Nakamura, M., and Ohno, T. (1995) Gene therapy with the radio inducible promoter Egr-1 activated by radioisotope that localizes to pancreatic cancer. Gene Ther. 2, 691, A074.
51. Williams, G. T. and Morimoto, R. I. (1990) Maximal stress-induced transcription from the human HSP70 promoter requires interactions with the basal promoter elements independent of the rotational alignment. Mol. Cell. Biol. 10, 3125-3136.
52. Gazit, G., Kane, S. E., Nichols, P., and Lee, A. S. (1995) Use of the stress-inducible grp78/BiP promoter in targeting high level gene expression in fibrosarcoma in vivo. Cancer Res. 55, 1660-1663.
53. Pantaleo, G., Graziosi, C., and Fauci, A. S. (1993) The immunopathogenesis of human immunodeficiency virus infection. New Engl. J. Med. 328, 327-335.
54. Buchschacher, G. L. and Panganiban, A. T. (1992) Human immunodeficiency virus vectors for inducible expression of foreign genes. J. Virol. 66, 2731-2739.
55. Buchschacher, G. L., Freed, E. O., and Panganiban, A. T. (1992) Cells induced to express a human immunodeficiency virus type 1 envelope gene mutant inhibit the spread of wild-type virus. Hum. Gene Ther. 3, 391-397.
56. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J. Virol. 65, 5531-5534.
57. Smythe, J. A., Sun, D., Thomson, M., Markham, P. D., Reitz, M. S., Gallo, R. C., and Lisziewicz, J. (1994) A Rev-inducible mutant gag gene stably transferred into T-lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci. USA 91, 3657-3661.
58. Liem, S. E., Ramezani, A., Li, X., and Joshi, S. (1993) The development and testing of retroviral vectors expressing trans-dominant mutants of HIV-1 proteins to confer anti-HIV-1 resistance. Hum. Gene Ther. 4, 625-634.
59. Calenda, V., Leissner, P., Sorg, T., Leroy, P., Marigliano, M., Touraine, J. L., Sanhadji, K., Pavirani, A., and Mehtali, M. (1994) Gene therapy for HIV infection. Gene Ther. 2, 589.
60. Venkatesh, L. K., Arens, M. Q., Subramanian, T., and Chinnadurai, G. (1990) Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc. Natl. Acad. Sci. USA 87, 8746-8750.
61. + cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected population. Proc. Natl Acad. Sci. USA 89, 182-186.
62. Harrison, G. S., Long, C. J., Curiel, T. J., Maxwell, F., and Maxwell, I. H. (1992) Inhibition of human immunodeficiency virus-1 production resulting from transduction with a retrovirus containing an HIV-regulated diphtheria toxin A chain gene. Hum. Gene Ther. 3, 461-469.
63. Chen, S.-Y., Bagley, J., and Marasco, W. A. (1994) Intracellular antibodies as a new class of therapeutic molecules for gene therapy. Hum. Gene Ther. 5, 595-601.
64. Palmer, T. D., Rosman, G. J., Osborne, G. R. A., and Miller, A. D. (1991) Genetically modified skin fibroblasts persist long after transplantation by gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA 88, 1330-1334.
65. Richards, C. A. and Huber, B. E. (1993) Generation of transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of transgene expression. Hum. Gene Ther. 4, 143-150.